India’s Drug Regulators Revisit 29 Controversial Vitamin-Mineral Combinations Amid Safety Concerns

February 18, 2026

NEW DELHI — India’s apex drug regulatory advisory body has reignited a high-stakes battle over pharmaceutical safety, launching a fresh investigation into 29 fixed-dose combination (FDC) medicines. These products, which combine multiple vitamins and minerals into a single pill, are being reassessed by a specialized subcommittee of the Drugs Technical Advisory Board (DTAB). The move comes amid persistent warnings from medical experts that these “irrational” combinations lack therapeutic justification and may pose unnecessary health risks to millions of consumers.

The Core of the Controversy: “Irrational” Formulations

The 29 combinations currently under the microscope are not new to regulatory scrutiny. They were originally flagged over a decade ago by the Kokate Committee, an expert panel tasked with reviewing the safety of thousands of FDCs sold in India.

The committee’s 2015 report categorized these specific vitamin-mineral blends as “irrational,” a clinical term used for drugs that:

• Lack a proven scientific rationale for combining the ingredients.

• Do not offer additional benefits over taking the ingredients separately.

• May cause “pharmacodynamic mismatches,” where ingredients interfere with each other’s absorption or efficacy.

Despite these earlier warnings, legal challenges and administrative delays allowed many of these products to remain on pharmacy shelves. The current review, led by Dr. Nilima Kshirsagar, a renowned clinical pharmacologist and former chair of the Indian Council of Medical Research (ICMR) subcommittee, aims to provide a final scientific verdict on whether these drugs should be banned or restricted.

Why FDCs Matter to Your Health

A fixed-dose combination (FDC) includes two or more active drugs in a single dosage form. While rational FDCs—such as those used to treat HIV or Tuberculosis—can improve patient compliance by reducing “pill burden,” experts warn that the Indian market is saturated with “cocktail” drugs created for commercial rather than medical reasons.

“The danger with irrational vitamin-mineral combinations isn’t always immediate toxicity,” explains a representative from the Central Drugs Standard Control Organisation (CDSCO). “The risk lies in chemical incompatibilities and ‘dosing mismatches.’ When you fix the ratio of five different vitamins in one pill, a doctor cannot adjust one without inadvertently overdosing the patient on another.”

Key Risks Identified by Researchers:

1. Reduced Efficacy: Some minerals can inhibit the absorption of specific vitamins when taken simultaneously.

2. Toxicity: Chronic intake of high-dose fat-soluble vitamins (like A, D, E, and K) in unscientific combinations can lead to systemic accumulation.

3. Antimicrobial Resistance: While the current 29 focus on vitamins, the broader crackdown on FDCs targets “irrational” antibiotic blends which, according to Dr. Ramanan Laxminarayan of the Center for Disease Dynamics, Economics and Policy, are a primary driver of drug-resistant “superbugs” in India.

A Decade-Long Regulatory Battle

The path to this week’s reassessment has been paved with litigation. In 2016, the Indian government moved to ban 344 FDCs, triggering a massive legal backlash from pharmaceutical giants. The Supreme Court of India eventually intervened in late 2017, mandating that the DTAB conduct fresh, evidence-based reviews for each disputed drug.

This systematic “cleansing” of the market has accelerated recently. In August 2024, the CDSCO banned 156 FDCs, followed by another 35 in April 2025. The current review of the 29 vitamin-mineral combinations is seen as one of the final chapters in this regulatory overhaul.

Public Health Implications: What This Means for You

For the average consumer, vitamin supplements are often viewed as “harmless” health boosters. However, medical professionals urge caution.

“Patients often assume that if a drug contains vitamins, it must be safe,” says a Delhi-based clinical pharmacologist. “But these are still pharmaceutical products. If the combination hasn’t undergone rigorous pharmacokinetic testing—which looks at how the body processes the drugs together—it shouldn’t be in your medicine cabinet.”

Practical Advice for Consumers:

• Audit Your Supplements: Check your prescriptions or over-the-counter supplements for long lists of combined ingredients.

• Consult Professionals: Ask your doctor if a single-ingredient supplement or a change in diet would be more effective than a multi-drug FDC.

• Be Aware of “State-Approved” Drugs: Historically, many irrational FDCs were approved by state authorities without central clearance. Recent federal crackdowns aim to close this loophole.

Potential Limitations and Industry Perspective

The pharmaceutical industry has argued that FDCs provide an affordable way for low-income populations to access multiple nutrients. Some industry advocates claim that banning these drugs could lead to “therapeutic gaps” and increased costs for patients who would have to buy individual components separately.

However, the Kshirsagar Subcommittee maintains that patient safety and scientific validity must take precedence over market convenience. The board is currently reviewing clinical data to determine if any of the 29 combinations offer a “genuine clinical advantage” that outweighs their potential risks.

The Path Forward

The subcommittee’s findings are expected to be submitted to the DTAB later this year. If the drugs are found to lack therapeutic justification, they will likely join the growing list of prohibited substances under the Drugs and Cosmetics Act, 1940. This move signals India’s commitment to aligning its pharmaceutical market with global standards of Antimicrobial Stewardship and rational medicine use as advocated by the World Health Organization (WHO).

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Medical Dialogues. “DTAB Sub-Panel to Reassess 29 ‘Irrational’ FDCs Flagged by Kokate Committee.” February 16, 2026.